Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | FAAH | O00519 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | RBP4 | P02753 | 3/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4075602 | 0.95 | EPHX2 (0.40) | EPHX2CNR2ALDH1A1HPGDLMNA | |
| SCHEMBL23912860 | 0.91 | FAAH (0.39) | EPHX2CNR2HPGDLMNAHTT | |
| SCHEMBL23912886 | 0.91 | CNR2 (0.37) | CNR2ALDH1A1HPGDLMNAHTT | |
| SCHEMBL23912846 | 0.90 | FAAH (0.43) | FAAHCNR1 | |
| SCHEMBL23912872 | 0.90 | LMNA (0.43) | EPHX2CNR2ALDH1A1LMNAHTT | |
| SCHEMBL24433948 | 0.88 | MEN1 (0.34) | ALDH1A1FAAHMEN1KMT2ACNR1 | |
| SCHEMBL4075700 | 0.86 | CNR2 (0.42) | EPHX2CNR2ALDH1A1HPGDLMNA | |
| SCHEMBL4084890 | 0.85 | CNR2 (0.43) | EPHX2CNR2ALDH1A1HPGDLMNA | |
| SCHEMBL4085241 | 0.84 | LMNA (0.48) | EPHX2CNR2ALDH1A1HPGDLMNA | |
| SCHEMBL4075138 | 0.84 | FAAH (0.43) | CNR2LMNAHTTFAAHCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11141404-B1 | Formulations and methods for treating acute cannabinoid overdose | ANEBULO PHARMACEUTICALS, INC. (US) | 2021-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11141404-B1 | Formulations and methods for treating acute cannabinoid overdose | CNR1, CNR2, FAAH | EPHX2 898/4885CNR2 2/4885ALDH1A1 3052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.